Tibolone
- 10 Dec 2023
- 1 Minute to read
- Print
- PDF
Tibolone
- Updated on 10 Dec 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
- Tibolone is a weakly androgenic, progestogenic and oestrogenic oral tablet.
- It should only be prescribed in post-menopausal women because it is a continuous-combined preparation.
- Because it has androgenic properties, it should not be prescribed with concomitant testosterone.
- Low-quality studies suggest that Tibolone might be a good choice in women with residual endometriosis. Although the reason for this is poorly understood, it has been suggested that this may be because it has oestrogenic effects on menopausal symptoms and bone, yet a progestogenic effect on tissues. More studies are required to confirm this.
- Tibolone may be associated with a small increased risk of stroke and caution is required in women with risk factors for stroke.
References and Further Information:
- Zanello M, Borghese G, Manzara F et al. Hormonal Replacement Therapy in Menopausal Women with History of Endometriosis: A Review of Literature. Medicine 2019. Found on page 6.
- Fedele L, Bianchi S, Raffaelli R et al. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas 1999.
Was this article helpful?